Dianax receives €2M grant from EU

The EU funds will allow Dianax to accelerate development and move into industrial phase

08-Jul-2016 - Italy

Dianax, the Italian medtech diagnostic start-up, received a €2million grant as part of the European Union framework programme supporting research and innovation in small and medium companies - Horizon 2020 SME. Dianax is developing a portable diagnostic lab-on-chip for the prevention and monitoring of diabetes, designed to provide immediate and precise onsite measurements of glycated haemoglobin.

The non-refundable grant from the European Commission will allow Dianax to accelerate the lab-on-chip development and move into industrial production phase sooner than initially planned.

"The EU funding is an important international recognition of the innovative value of our technology - stated Eugenio Iannone, Dianax Co-Founder and CEO - and a significant booster for our roadmap to market entry".

New test may predict COVID-19 immunity

Paper test measures the level of neutralizing antibodies in a blood sample and could help people decide what protections they should take against infection

Read news

Dianax' potential beyond diabetes

"Dianax' lab-on-chip is a platform technology that can be potentially applied to any protein biomarkers in biological fluids, such as blood, urine or saliva.

"Dianax innovation could help address a number of key diagnostics and medical issues for a large number of patients and for the healthcare system in general," explained Francesco Granata, Partner and Advisor at Dianax. The possible use of Dianax' portable diagnostic device range from patients' self or home monitoring, to prompt diagnostic tests at healthcare settings, such as chemist's stores, doctor's practices and hospitals, to emergency care at A&E departments or on the ambulance, potentially allowing prompt assessment of conditions or treatment effects.

"As about half of commonly used blood tests consists in measuring proteins - confirmed Iannone - our technology has extensive potential in portable diagnostics".

The Dianax device is based on a unique patented technology capable of performing extremely precise clinical analysis from a drop of blood in a simple and portable way. In fact, the Dianax lab-on-chip is fast (yields results in few minutes), extremely resistant to vibration, to high/low temperatures, durable (up to two years), versatile (easy to use and potentially integrated with smartphones) and low-cost, which make it extremely attractive compared to alternative products.

Dianax' chip has potential applications beyond the medical field, such as in environmental and food control, in biological and medical research and in the veterinary sector.

https://www.bionity.com/en/news/158841/dianax-receives-2m-grant-from-eu.html